交易 Syndax Pharmaceuticals, Inc. - SNDX 差價合約

交易條件

• 類型該金融市場可進行差價合約交易。了解更多：差價合約: 差價合約
• 點差: 0.07
• 長倉隔夜倉息調整長倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用-0.022179 %(-$0.44)使用杠杆的交易規模（大約值）$2,000.00來自杠杆的資金 - 美元（大約值）$1,000.00前往平台: -0.02218%
• 短倉隔夜倉息調整短倉隔夜倉息調整保證金。您的投資$1,000.00隔夜倉息來自頭寸全值的費用-0.000043 %(-$0.00)使用杠杆的交易規模（大約值）$2,000.00來自杠杆的資金 - 美元（大約值）$1,000.00前往平台: -0.00004%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: USD
• 最低成交量: 1
• 保證金: 50.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價保證止損 (GSL) 費用僅在 GSL 被觸發時收取。更多詳情請參閱我們網站的「服務費用」 頁面。: 1%

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: -0.022179 %
  (-$0.44)

• 保證金。您的投資: $1,000.00
• 隔夜倉息來自頭寸全值的費用: -0.000043 %
  (-$0.00)

主要統計數據

• 前收盤價: 16.86
• 開倉: 16.87
• 1 年變化: 2.55%
• 日區間: 16.76 - 17.29

交易 Syndax Pharmaceuticals, Inc. - SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.